FDA approved Bayer HealthCare LLC’s novel vasodilator Adempas (riociguat) Oct. 8 with labeling that reflects the higher dosing schedule proposed by the sponsor despite agency reviewers’ reservations about the risks of hypotension with the suggested dose.
However, labeling provides the option for a lower starting dose in patients who may not tolerate the drug’s hypotensive effects....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?